Small cell lung cancer (SCLC) is an aggressive, rapidly metastazising neoplasm with a high propensity for marrow involvement. SCLC cells express high levels of functional CXCR4 receptors for the chemokine stromal-cell-derived factor-1 (SDF-1/CXCL12). Adhesion of SCLC cells to extracellular matrix or accessory cells within the tumor microenvironment confers resistance to chemotherapy via integrin signaling and thus may be responsible for residual disease and relapses commonly seen in SCLC. We examined the signaling mechanisms that regulate CXCL12-induced adhesion of SCLC cells to fibronectin, collagen, and stromal cells and the effects on SCLC cell chemoresistance. We found that CXCL12-induced integrin activation which resulted in an increased adhesion of SCLC cells to fibronectin and collagen. This was mediated by a2, a4, a5, and b1 integrins along with CXCR4 activation, which could be inhibited by CXCR4 antagonists. Stromal cells protected SCLC cells from chemotherapy-induced apoptosis, and this protection could also be antagonized by CXCR4 inhibitors. We conclude that activation of integrins and CXCR4 chemokine receptors co-operate in mediating adhesion and survival signals from the tumor microenvironment to SCLC cells. Therefore, CXCR4 antagonists in combination with cytotoxic drugs should be explored in SCLC to overcome CXCL12-mediated adhesion and survival signals in the tumor microenvironment.
Introduction
Small cell lung cancer (SCLC) is a particularly aggressive form of lung cancer. The early and widespread metastasis and the ability to develop resistance against chemotherapeutic drugs (Ihde, 1992; Hoffman et al., 2000) are responsible for the highly malignant phenotype of SCLC. SCLC has a striking tendency to metastasize in the bone marrow (Lassen et al., 1995) . Metastasis of cancer cells involve the passage through the blood and/or lymphatic circulation and movement across vascular barriers. It is believed that metastatic cancer cells co-opt signals that normally control leukocyte trafficking, such as chemokine-mediated cell migration. According to the multistep paradigm of leukocyte migration, emigration from the vasculature and tissue homing is regulated by a sequence of distinct molecular signals (Springer, 1994) . One key step of this sequence involves chemokines that activate integrins and direct the migration of leukocytes.
The chemokine stromal-cell-derived factor-1 (SDF-1/ CXCL12) is a CXC chemokine constitutively expressed by marrow stromal cells. CXCR4, the sole CXCL12 receptor, plays a pivotal role for the homing of hematopoietic stem cells within the marrow microenvironment. There is growing evidence that the CXCR4/ CXCL12 axis regulates migration and metastasis of a variety of cancers (Burger et al., 1999; Geminder et al., 2001; Muller et al., 2001; Robledo et al., 2001; Taichman et al., 2002) . In vivo neutralization of the CXCR4/ CXCL12 axis resulted in inhibition or attenuation of metastases of breast cancer and NSCLC (Muller et al., 2001; Phillips et al., 2003) . Because SCLC has a striking tendency to metastazise to the bone marrow (Hoffman et al., 2000) and marrow stromal cells secrete high amounts of CXCL12, we hypothesize that the CXCR4/ CXCL12 interaction is also involved in SCLC metastasis and protection from apoptosis in the tumor microenvironment.
CXCR4 engagement by CXCL12 leads to diverse biological responses, some of which are cell-type dependent. Binding of CXCL12 to CXCR4 induces activation of Gai proteins, the phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein (MAP) kinase pathways in a range of cell types, including tumor cells like SCLC (Ganju et al., 1998; Vicente-Manzanares et al., 1998; Kijima et al., 2002; Burger et al., 2003b) . CXCL12 can activate integrins and initiate firm adhesion of rolling leukocytes (Campbell et al., 1998; Constantin et al., 2000) . It is suggested that CXCR4/ CXCL12 interaction mediates cytoskeletal changes, since stimulation of CXCR4 transfectants by CXCL12 resulted in increased phosphorylation of focal adhesion components, including the related adhesion focal tyrosine kinase (RAFTK/Pyk2), Crk and paxillin (Ganju et al., 1998) .
The integrins are a family of cell adhesion receptors that mediate the binding and responses of cells to extracellular matrix (ECM). They are involved in cell-ECM as well as in cell-cell interactions. Sethi et al. (1999) demonstrated that, in vivo, SCLC cells exist in an ECM-rich environment at both primary and secondary metastatic sites. The ECM stroma, which surrounds SCLC cells, contains fibronectin, laminin, collagen IV and tenascin. On the other side, SCLC cells express various a-and b-integrin chains that allow for interactions with the ECM containing tumor microenvironment. Correspondingly, adhesion of SCLC cells to ECM enhanced tumorigenicity of SCLC cells, induced a b1-integrin-stimulated tyrosine kinase activation, and resistance to chemotherapeutic agents (Sethi et al., 1999) . Recently we demonstrated that CXCL12 enhanced the adhesion of SCLC cells to immobilized VCAM-1, demonstrating that CXCR4 receptors can induce integrin activation on SCLC cells (Burger et al., 2003b) . In addition, CXCR4/CXCL12 interaction induced actin polymerization and firm adhesion of SCLC cells to marrow stromal cells, suggesting that this interaction may be involved in adhesive and migratory events in the bone marrow metastasis of SCLC cells.
In this study we further investigated the interaction between the CXCR4 signaling and the protective effect of b1-integrin engagement in SCLC cells. We demonstrate that SCLC cell adhesion to b1-integrin ligands fibronectin and collagen is increased by CXCL12. Rho GTPases are involved in the CXCL12-induced adhesion of SCLC cells and the focal-adhesion adaptor protein paxillin is activated by CXCL12 in NCI-H82 and NCI-N592 cells. Locking integrins in activated state by Manganese as well as coimmobilized CXCL12 partially reduces the chemosensitivity of SCLC cells. Moreover, we demonstrate that adhesion of SCLC cells to marrow stromal cells protects them from etoposide-induced apoptosis, which can be antagonized by CXCR4-specific antagonists and antibodies against a4 integrins.
Results

CXCL12 enhances adhesion to fibronectin and collagen
Previously we demonstrated that CXCL12 enhanced the adhesion of SCLC cells to immobilized VCAM-1, demonstrating that CXCR4 chemokine receptors can induce VLA-4 activation on SCLC cells. Sethi et al. (1999) showed that the adherence of SCLC cells to ECM proteins fibronectin and collagen protected the SCLC cells from chemotherapy-induced apoptosis. Adhesion assays were performed to test whether the SCLC cell adhesion to fibronectin and collagen is mediated by CXCR4/CXCL12 interaction. Using three different common SCLC cell lines we found that a part of the SCLC cells became adherent to fibronectin without stimulation. The percentage of cells being adherent without further stimulus differed from cell line to cell line, NCI-N592 cells showed the highest background adhesion to fibronectin. The adherence to fibronectin was significantly enhanced by coimmobilized CXCL12 in all tested cell lines (Figure 1a ). To rule out unspecific adhesion, control wells were precoated with BSA instead of fibronectin or collagen. No adherent SCLC cells were detected in this case (data not shown), indicating that adhesion was dependent on fibronectin or collagen. Whereas all three SCLC cell lines showed background adhesion to fibronectin, only SCLC cell line NCI-N592 showed background adhesion to collagen. We observed a very robust activation of adhesion to collagen by coimmobilized CXCL12 in all three tested cell lines (Figure 1b) .
a2-, a4-and a5-, as well as b1-integrin subunits are involved in the CXCL12-induced adhesion to fibronectin and collagen. We found high expression of integrin subunits a4 and a5 as well as b1 in SCLC cells (Figure 2 ). NCI-N592 also expressed a2-integrin subunits (Figure 2b ). a3 expression was usually low; and a1 and b7 expression was absent in SCLC cells. Accordingly, CXCL12-induced adhesion of NCI-H82 cells to fibronectin could be inhibited with a4 as well as a5 blocking antibodies (Figure 1c ). CXCL12-induced adhesion of NCI-H69 and NCI-N592 cells to collagen could be inhibited with a2 blocking antibodies but not with a1 or a3 blocking antibodies (Figure 1d ). Isotype controls of the antibodies did not block adhesion to fibronectin or collagen.
Furthermore we tested if the CXCL12-induced adhesion to fibronectin and collagen could be inhibited with CXCR4 antagonist T140 and PT (Figure 1e and f). Whereas T140 significantly inhibited the CXCL12-induced adhesion, PT showed no inhibition, indicating that the CXCL12-induced adhesion to fibronectin is not Gai mediated. In summary, our data indicate that the adhesion of SCLC cells to ECM components is mediated by CXCR4/CXCL12 interaction.
Rho kinase is involved in CXCL12 modulation of VLA-4-mediated SCLC cell adhesion CXCL12 activates p44/42 MAP kinase as well as PI3 kinase in SCLC cells (Kijima et al., 2002; Burger et al., 2003b) . We tested whether these pathways are necessary for the CXCL12-induced cell adhesion (Figure 3 ). Additionally, we tested whether src kinases are necessary for the CXCL12-induced adhesion. There was no inhibition of adhesion by PD98059, LY294002 and src kinase inhibitors PP1 and PP2 (data not shown). However, adhesion could be inhibited with Rho kinase inhibitor Y27632 and Toxin B, an inhibitor for the small Rho GTPases Rho, Rac and Cdc42. This suggests that Rho GTPases are involved in mediating CXCL12-induced adhesion of SCLC cells to VCAM-1 (Figure 3 ).
Tyrosine phosphorylation of components of focal adhesion complexes
Focal adhesions that contain part of the cytoskeleton and plasma membrane are structures that mediate adherent contacts with the ECM. The focal adhesion kinase (FAK) is thought to play an important role in cell adhesion and migration (Schaller, 2001) , and the focal adhesion components paxillin and CrkL are thought to play important roles in chemotactic signaling pathways (Ganju et al., 1998) . Therefore we assessed FAK, paxillin and CrkL phosphorylation upon CXCL12 stimulation in SCLC cell lines NCI-H69, NCI-H82 and NCI-N592. All three cell lines tested showed (a) SCLC cell adhesion to immobilized fibronectin is enhanced by CXCL12. Cells were allowed to adhere 30 min to fibronectin coated wells (10 mg/ml). Adhesions were quantified using CyQuant Cell Proliferation Kit. Coimmobilized CXCL12 (8 mg/ml) induced a significant increase in SCLC cell adhesion to fibronectin in SCLC cell lines NCI-H69, NCI-H82 and NCI-N592, as indicated by the asterisks depicted above the bars with Pp0.05. The black bars represent the relative proportion of adhering SCLC cells in comparison to SCLC cell adhesion to fibronectin without CXCL12 (gray bars). Adhesion data represent the mean and s.e.m. of at least five independent experiments, measured in quatriplicate samples. (b) SCLC cell adhesion to immobilized collagen I is enhanced by CXCL12. Cells were allowed to adhere 30 min to collagen coated wells (5 mg/ml). Adhesions were quantified using CyQuant Cell Proliferation Kit. Coimmobilized CXCL12 (8 mg/ml) induced a significant increase in SCLC cell adhesion to collagen I (Pp0.05). Adhesion data represent the mean and s.e.m. of at least five independent experiments, measured in quatriplicate samples. (c) CXCL12-mediated adhesion to fibronectin is a4 and a5 integrin dependent. NCI-H82 cells were preincubated with 5 mg/ml a4 and a5 blocking antibodies and the corresponding isotype control. One of two independent experiments, measured in quatriplicate, is shown. (d) CXCL12-mediated adhesion to collagen is a2, but not a1 or a3 dependent. NCI-N592 cells were preincubated with 20 mg/ml a1, a2, and a3 blocking antibodies and the corresponding isotype control. One of two independent experiments, measured in quatriplicate, is shown. (e) CXCL12-mediated adhesion of SCLC cells onto fibronectin is CXCR4, but not Gai dependent. NCI-H82 cells were preincubated with CXCR4 antagonist T140 (300 mg/ml) and PT (500 ng/ml), an inhibitor of Gai proteins. Inhibition of CXCR4 but not of Gai decreased the adhesion to fibronectin, suggesting that Gai proteins are not involved in CXCR4-mediated b1-integrin activation. Results are shown as specific adhesion (background adhesion in the absence of a stimulus was subtracted from CXCL12-induced adhesion). The experiment was performed three times in quatriplicate each and mean values7standard errors are shown. (f) CXCL12-mediated adhesion of SCLC cells onto collagen is CXCR4, but not Gai dependent. NCI-H82 cells were preincubated with T140 and PT as described in (e). Mean values7standard errors from three independent experiments are shown The expression of paxillin is usually very low or nonexistent in SCLC samples (Salgia et al., 1999) . In NCI-H69 phosphorylated paxillin was undetectable, but in NCI-H82 and NCI-N592 cells, paxillin phosphorylation increased about 50% upon CXCL12 stimulation (Figure 4c ), as confirmed by densitometrical measurements of the blots.
Soluble CXCL12 (sCXCL12) does not have direct proliferative or protective effects on SCLC cells
It has been suggested that CXCL12 may have a proliferative effect on SCLC cells (Kijima et al., 2002) . We performed several experiments to reveal a possible proliferative or antiapoptotic effect of CXCL12 on SCLC cells. First, cell proliferation was evaluated 48 h after stimulation by CXCL12 using the colorimetric MTT assay. Up to 500 ng/ml CXCL12 had no effect on proliferation of NCI-H69, NCI-H82 and NCI-N592 cells (data not shown). Second, apoptosis was induced by culturing SCLC cells in serum-free medium, and SCLC cell viability was cytometrically determined with DIOC 6 /PI after 48 h, to test if there is an antiapoptotic effect of CXCL12. We found that the addition of sCXCL12 to media did not improve the survival of serum-starved cells (data not shown). Third, we cultivated NCI-H82 and NCI-N592 cells in full medium or serum-free medium and treated them with 100 or 200 mg/ml etoposide for 48 h to induce apoptosis Pathways involved in CXCL12 modulation of VLA-4-mediated SCLC cell adhesion. CXCL12-mediated adhesion of SCLC cells is Rho dependent. NCI-N592 cells were preincubated with 20 mM PD98059, 10 mM Y27632 and 100 ng/ml Toxin B. Cells were allowed to adhere 30 min to VCAM-1 (1.3 mg/ml) and CXCL12 (8 mg/ml) coated wells. Adhesions were quantified using CyQuant Cell Proliferation Kit. Results are shown as specific adhesion (background adhesion in the absence of a stimulus was subtracted from CXCL12-induced adhesion). The experiment was performed four times in quatriplicate each and mean values7 standard errors are shown. The asterisk indicates significant differences to the control with Pp0.05 CXCR4 and integrin signaling in SCLC TN Hartmann et al ( Figure 5 ). Addition of sCXCL12 to media could in neither case protect NCI-H82 and NCI-N592 cells from etoposide-induced apoptosis (Figure 5a-c) . To test whether cell adhesion induced by CXCL12 and integrin ligands coplated on plastic is sufficient to enhance etoposide resistance, we used fibronectin and immobilized CXCL12. As previously described by Sethi et al. (1999) , fibronectin protected the SCLC cells against etoposide-induced apoptosis, but we could not find an additional CXCL12 effect, when cells were cultivated with fibronectin and CXCL12 (data not shown). However, precoating the culture plates with CXCL12 had a significant protective effect on etoposide-induced apoptosis of NCI-N592 cells in serum-free medium (Figure 5c ), but this effect could not be seen in full medium with 10% fetal calf serum (FCS) (Figure 5b) . Moreover, the integrins were locked in activated state by addition of Manganese ions which led to strong adhesion of the cells to the plates. SCLC cells cultivated in full medium were significantly protected from etoposide-induced apoptosis by the addition of Manganese, whereas there was no protective effect in serum-free medium (Figure 5b and c) . As additional controls, SCLC cells were treated with CXCL12 or Manganese without etoposide. In serum-free medium, Manganese reduced the viability of NCI-N592 cells about 30%. This may be one possible explanation for the result that Manganese did not protect the SCLC cells from etoposide-induced apoptosis in serum-free medium.
Stromal cells protect SCLC cells against etoposideinduced apoptosis -antagonization by TN14003
M2-10B4 marrow stromal cells secrete high levels of bioactive CXCL12 (Burger et al., 1999) . We previously showed that the adhesion of SCLC cells to stromal cells is dependent on CXCR4/CXCL12 interaction (Burger et al., 2003b) . We now investigated the protective effect of marrow stromal cells against etoposide-induced apoptosis of SCLC cells. CXCR4-specific antagonists were used to inhibit the protective effect of stromal cells.
NCI-H82 and NCI-N592 cells were cultivated with or without M2-10B4 cells and treated with 100 mg/ml etoposide or combinations of etoposide and TN14003 (Figure 6a and b) . SCLC cells were stained with CD56-PE to distinguish from M2-10B4 cells and cell viability of SCLC cells was determined after 48 h. Growth on M2-10B4 did not improve the viability of NCI-H82 cells, but slightly improved viability of NCI-N592 cells (Figure 6d TN14003 antagonizes the protective effect of the marrow stromal cells supposedly by affecting the CXCL12-induced integrin upregulation and adhesion to stroma. It is known that M2-10B4 cells express integrin ligands laminin, collagen IV and fibronectin (Zipori et al., 1985; Lemoine et al., 1988) . VCAM-1 secretion of M2-10B4 cells was from 3 to 6 ng/ml VCAM-1 during the 48 h incubation time in our experimental settings. This high concentration of the a4b1 ligand VCAM and our previous results on the influence of a4b1 for the adhesion of SCLC cells to stromal cells (Burger et al., 2003a) suggests a role of a4 in the CAM-DR. We tested the contribution of integrin subunits on SCLC by using blocking antibodies to a4-and a5-integrin subunits. Preincubation of SCLC cells with a4 blocking antibody significantly decreased chemoresistance compared to control experiments without blocking antibody (Figure 6c ). Pretreatment with a5 blocking antibodies had less effect than pretreatment with four blocking antibodies. Altogether, the protective effect of stromal cells is caused by CXCR4 along with integrin activation. 
Discussion
Although the majority of advanced stage SCLC patients initially display impressive responses to chemotherapy, SCLC almost invariably relapses, becomes resistant to treatment and therefore remains an incurable disease. Sethi et al. (1999) previously demonstrated that adhesion of SCLC cells to accessory cells or ECM within the tumor microenvironment protects SCLC cells from cytotoxic drugs commonly used to treat SCLC patients. This mechanism of primary resistance is, at least partially, mediated via signaling through integrins expressed on SCLC cells and may be responsible for minimal residual disease and relapses. However, integrin activation generally is connected to chemokine receptor activation, a model that initially was developed to explain leukocyte transendothelial migration ('multistep paradigm') (Springer, 1994) . It has been shown by several groups that CXCR4 enhances adhesion of hematopoetic cells and tumor cells to vascular endothelium (Peled et al., 1999; Murakami et al., 2002) .
Previously we reported that SCLC cells express high levels of functional CXCR4 receptors (Burger et al., 2003b ). Here we demonstrate that b1-integrin-dependent resistance mechanisms of SCLC cells are partly mediated by CXCR4 signaling. Our results indicate that CXCL12/CXCR4 are important mediators for the adherence of SCLC cells to ECM proteins like fibronectin, collagen I and VCAM-1. CXCR4-induced adhesion of SCLC cells to marrow stromal cells protected them against etoposide-induced apoptosis. The protective effect of the marrow stromal cells could be antagonized by CXCR4-specific inhibitors and antibodies against a4 integrins.
Looking at signaling components involved in adhesion, we found that CXCL12 treatment induced the phosphorylation of the focal adhesion complex component paxillin. Focal adhesions are structures that mediate adherent contacts with the ECM. In accordance with our results on SCLC cells, paxillin phosphorylation in response to CXCL12 was recently found in breast cancer cells (Fernandis et al., 2004) . Paxillin serves as a binding site for a number of important signaling and structuring molecules including vinculin, talin, Crk, Crk-L, p130Cas and Src (Hamasaki et al., 1996; Ganju et al., 1998; Duong and Rodan, 2000; Wade et al., 2002) . In contrast to the situation in breast cancer cells (Fernandis et al., 2004) , we found constitutive activation of FAK and Crk-L in SCLC cells. Furthermore, our group and others reported that CXCL12 activates PI3 K (Kijima et al., 2002; Burger et al., 2003a) . To study whether PI3K was involved in the CXCL12-triggered cell adhesion, we preincubated the cells with the PI3K inhibitor LY294002, which however did not affect the upregulation of adhesion to VCAM-1 by CXCL12. Moreover, the MEK inhibitor PD98059 did not influence CXCL12-induced adhesion, which implies that the MAP kinase pathway does not contribute to integrin activation in SCLC cells. Similar observations have been made in REH pro-B cells, in bone-marrow-derived leukemia and myeloma cell lines Sanz-Rodriguez et al., 2001; Glodek et al., 2003) .
CXCR4 is a Gai-coupled receptor, and Pertussis toxin (PT) is an agent that catalyses the ADP ribosylation of specific G protein a subunits of the Gi family, preventing receptor-G protein interactions. However, PT only partially reduced the enhancement of static adhesion of SCLC cells to VCAM-1, fibronectin and collagen coimmobilized with CXCL12. These data indicate that also Gai-independent signaling must be involved in CXCL12 enhanced adhesion. In accordance with our findings Wright et al. (2002) demonstrated in a study on lymphocytes that PT completely blocked chemotaxis, but the a4b7-dependent adhesion of B and T lymphocytes triggered by CXCL12 was only partially inhibited by PT. In the same work Wright et al. reported that inhibition of RhoA activation reduced the upregulation of a4b7-dependent adhesion, suggesting that activation of RhoA is an important step in the signaling leading to increased adhesion. This goes in line with our present findings that inhibition of Rho kinase and small Rho GTPases leads to a reduction in CXCL12-triggered adhesion to b1 integrins.
The adherence of SCLC cells to ECM proteins fibronectin, collagen I and VCAM-1 is mediated by various integrins. As we demonstrated by using blocking antibodies, activation of a2, but not of a1-or a3-integrin subunits were involved in the CXCL12-induced adhesion to collagen. Both, activation of a4-and a5-integrin subunits contributed to the SCLC adhesion to fibronectin, but blocking the a5 subunit led to a stronger decrease than blocking of the a4 subunit. The CXCL12-induced adhesion to VCAM-1, fibronectin, and collagen was completely inhibited by pretreatment of the SCLC cells with the CXCR4 antagonist T140, a 14-residue peptide with highly specific CXCR4 antagonistic activities. Sethi et al. (1999) were the first who demonstrated that b1-integrin activation promotes growth and survival of SCLC cells. They found that this b1-integrindependent resistance mechanism to chemotherapy was mediated by a protein tyrosine kinase-dependent mechanism. Subsequent, Kraus et al. (2002) found that variant SCLC cell lines NCI-H69ad and NCI-N592ad, that have been subcultivated and selected for adherent growth, showed increased chemo-and radio-resistance with constitutive activation of AKT and MAP kinase pathways and upregulation of integrins a2, a3 and b4. In addition, integrin-mediated adhesion of myeloma cells to fibronectin (Hazlehurst et al., 2000) and of glioma cells to vitronectin (Uhm et al., 1999) induced drug resistance. These studies led to the hypothesis that cellmatrix interactions at the tumor-stroma interface are able to confer resistance to apoptosis, a phenomenon referred to as cell adhesion-mediated drug resistance (CAM-DR). Although it has not yet been clearly established whether such a mechanism might account for the acquired resistance found in SCLC, CAM-DR could perhaps explain the local recurrence of SCLC often seen clinically after chemotherapy.
The data of our study suggest that CXCR4 mediates the b1-integrin-dependent adhesion of SCLC cells to ECM proteins. Previously we have shown that stromal cell adhesion of SCLC cells was significantly inhibited by the specific CXCR4 antagonist T140, anti-CXCR4 antibodies, anti-VCAM-1 antibodies, and CS-1 peptide. This demonstrates the involvement of CXCR4 chemokine receptor activation and a4b1-integrin binding in the adhesion of SCLC cells to stroma (Burger et al., 2003b) . Marrow stromal cells are a dominant source of CXCL12 in vivo and retain their capacity to secrete high amounts of this chemokine in vitro (Burger et al., 1999) . Here, we demonstrate that the adhesion to marrow stromal cells protected SCLC cells against etoposide-induced apoptosis. This seems to be dependent on CXCR4 and integrin signaling, since pretreatment of SCLC cells with TN14003 and antibodies against a4 integrin could antagonize the protective effect of marrow stromal cells on etoposide-induced apoptosis. Whereas sCXCL12 did not have any effect on the survival of SCLC cells after etoposide treatment, immobilized CXCL12 increased SCLC survival under serum-free culture conditions. This suggests that juxtaposition of the chemokine and integrin ligand is necessary to stimulate integrinmediated adhesion that leads to the increased chemoresistance. Similar to our observation Grabovsky et al. (2000) and Peled et al. (1999) demonstrated that for the rapid triggering of VLA-4 adhesions of T lymphocytes or hematopoetic progenitors (HPC) surface-bound CXCL12 was necessary and could not be induced by soluble chemokines.
Locking the integrins in activated state by Manganese had a strong protective effect on etoposide-induced apoptosis in full medium. This suggests, that the integrin activation is sufficient to protect from etoposide-induced apoptosis independent of the factor that induced the activation. For our model on CXCL12-mediated CAM-DR, we suggest that CXCR4 mediates b1-integrindependent adhesion to ECM components, which then leads in several other steps, e.g. tyrosine kinase signaling, to resistance. Accordingly, CAM-DR of myeloma cells against mitoxantrone involves cell-cell adhesion of bone marrow stromal cells with myeloma cells as well as soluble factors induced by this cell-cell interaction (Nefedova et al., 2003) .
In summary, our results support the concept of CAM-DR described by Sethi et al. (1999) and show for the first time the involvement of CXCR4 in this concept. Signals from CXCR4 receptors may induce integrin activation resulting in resistance to chemotherapy-induced apoptosis in SCLC. The CXCR4 antagonist T140 and its derivates blocked the CXCR4-mediated adhesion to ECM components and thereby affected SCLC chemosensitivity. Thus, CXCR4 antagonists like T140 seem to be promising new therapeutic tools for improving the treatment of SCLC.
Materials and methods
Cell culture, chemokines, antibodies
The SCLC cell lines NCI-H82, NCI-H69, NCI-H446, NCI-N592, belonging to the classic subclass of SCLC, and the murine stromal cell line M2-10B4 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were maintained in RPMI 1640 medium containing 10% FCS and penicillin-streptomycin-glutamine (Gibco-BRL, Grand Island, NY, USA).
Synthetic human CXCL12 was purchased from Upstate Biotechnology (Lake Placid, NY, USA). Etoposide was purchased from Sigma-Aldrich (Munich, Germany). Antibody against phospho-CrkL was purchased from Cell Signalling Technology Inc. (Beverly, MA, USA). Antibodies against CrkL and phosphotyrosine, clone 4G10 were obtained from Upstate Biotechnology. Antibodies against phospho-FAK, FAK and paxillin were purchased from Santa Cruz Biotechnology Inc. (Heidelberg, Germany). The inhibitors T140, a 14 amino-acid residue peptide and its derivates TC14012 and TN14003, that possess higher stability in serum (Tamamura et al., 2001; Fujii et al., 2003) , were developed and kindly provided by N Fujii (Kyoto, Japan). PT and PD98059 were purchased from Merck (Darmstadt, Germany). Y27632 was purchased by Tocris Cookson Inc. (Ellisville, MO, USA). Toxin B was friendly provided by K Aktories (Freiburg, Germany).
Immunoprecipitation and Western blotting
SCLC cells were serum starved for 4 h, and lysates from 5 Â 10 6 cells per sample were prepared after stimulation with 100 ng/ml CXCL12 at the indicated time points. Lysis buffer was 20 mM Tris/HCl, pH 8.0, 150 mM KCl, 1 mM EDTA, 0.2 mM Na 3 VO 4 , 1% Triton X, 0.5 mM PMSF, protein inhibitor cocktail (complete s , Roche Applied Science, Penzberg, Germany). Equal amounts of protein were separated by 10% SDSpolyacrylamide gel electrophoresis (PAGE) and transferred onto PDVF membranes. Western blot analysis was performed using the appropriate antibodies recognizing the phosphorylated form of the proteins or the total proteins. Immunoreactive bands were visualized using horseradish peroxidase-conjugated secondary antibody and the enhanced chemiluminescence system (Amersham Biosciences, Freiburg, Germany).
For phospho-paxillin detection immunoprecipitations were performed using lysates prepared from SCLC cells. Phosphotyrosine antibodies (3.5 mg) were added; and the samples were incubated overnight at 41C. Immunoprecipitates were collected with 30 ml Protein G Sepharose beads (Zymed, San Francisco, CA, USA) for 2 h at 41C. They were washed three times with lysis buffer, fractionated by SDS-PAGE and immunoblotted with paxillin antibody.
SCLC cell adhesion to immobilized VCAM-1, fibronectin and collagen
In all, 96-well plates (Nalge Nunc International, Rochester, NY, USA) were coated with recombinant human VCAM-1 (R&D Systems, Minneapolis, MN, USA, 1.3 mg/ml) or fibronectin (BD Biosciences, Heidelberg, Germany, 10 mg/ml) or Collagen I (Sigma-Aldrich, Munich, Germany, 5 mg/ml) prepared in bicarbonate buffer (pH 9.6) and incubated overnight at 41C. Wells were then washed three times with bicarbonate buffer and coated with recombinant human CXCL12 prepared at 8.0 mg/ml in bicarbonate buffer for 30 min at room temperature or with the buffer alone. Wells were subsequently washed and blocked with 1% tissue culture BSA (Sigma) in PBS for 1 h at 371C, followed by washing with Hank's Balanced Salt Solution (HBSS) supplemented with 10 mM HEPES, pH 8.0. Cells were preincubated with different inhibitors, washed in PBS and resuspended at 10 5 per 50 ml of adhesion medium (HBSS buffered with HEPES and supplemented with 0.5% BSA). Cells were added in quatriplicate to the wells and allowed to settle for 30 min at 371C, followed by four washes with adhesion medium to remove nonadhered cells. The number of adhered cells was determined using CyQUANT Cell Proliferation Kit (Molecular Probes, Eugene, OR, USA) and fluorescence of the samples was measured by a Microtiter Plate Fluorometer.
Measurement of cell viability and expression of integrin subunits
For all experiments, viability of SCLC cells was routinely determined by trypan blue exclusion. In chemosensitivity experiments, determination of SCLC cell viability was based on the analysis of mitochondrial transmembrane potential by 3,3 0 dihexyloxacarbocyanine iodine (DIOC 6 ) and cell membrane permeability to propidium iodide (PI). In all, 48-well plates were precoated with 100 ml 8 mg/ml CXCL12 or BSA (controls). Cells were resuspended at 10 5 per 500 ml of serumfree RPMI or full medium. In all, 500 ng/ml CXCL12 and 1 mM MnCl 2 was added where indicated. After 48 h SCLC cells were collected and viability was determined in RPMI 1640 containing 0.5% BSA, 10 nM DIOC 6 (Molecular Probes) and 2 mg/ml PI (Molecular Probes) in RPMI 1640, 0.5% BSA. Cells were then incubated at 371C for 20 min and analysed within 30 min by flow cytometry on a FACSCalibur (Becton Dickinson, Mountain View, CA, USA). Flow cytometry data were analysed using the FlowJo 3.3 software (Tree Star Inc., San Carlos, CA, USA).
Expression of integrins was determined using monoclonal anti-CD49a, anti-CD49b, anti-Cd49c, anti-CD49d, antiCD49e and anti-CD29 antibodies and the appropriate isotype controls from Chemicon International Inc. (Temecula, CA, USA). SCLC cells were adjusted to a concentration of 10 6 cells/ ml in RPMI 1640, 0.5% BSA. A total of 10 5 cells was stained with saturating antibody concentrations for 30 min at 41C and afterwards washed two times. In cases of indirect antibody labeling, cells were incubated with appropriate secondary antibody and again washed two times. Integrin expression was analysed on the FACSCalibur.
SCLC-stromal cell adhesion assay
The murine stromal cell line M2-10B4 that secretes high amounts of CXCL12 (Burger et al., 1999) was seeded the day before the assay onto 24-well plates at a concentration of 0.5 Â 10 5 cells per well in RPMI-1640 supplemented with 10% FCS. In some cases, SCLC cells were preincubated with 100 mg/ml TN14003 or 20 mg/ml blocking antibodies against a4-, a5-or b1-integrin subunits for 30 min at 371C, and seeded on the stromal cell layer at a concentration of 2 Â 10 5 cells per well. Controls were seeded onto 24-well plates without stromal cells. After 4 h at 371C in 5% CO 2 , cells were treated with 100 mg/ml etoposide and incubated for another 48 h at 371C. In order to distinguish SCLC cells from stromal cells during the flow cytometry-based analysis of SCLC cell adhesion to stromal cells, SCLC cells were labeled with CD56-PE for 30 min at 41C and afterwards incubated with 100 nM DIOC 6 in RPMI 1640 medium with 0.5% BSA. Viability of SCLC cells was analysed by flow cytometry.
Statistical analysis
For statistical analysis, the paired Student's t-test for comparison of two groups was used. Analyses were performed with the statistic tool of Origin 7G, OriginLab Corporation (Northampton, MA, USA). Values were considered significant when Po0.05.
